Healthcare Services company Molbio Diagnostics announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations: The consolidated revenue for Q1FY27 stood at Rs 4,083.76 million, representing a substantial growth of 309.57% from Rs 997.08 million in Q1FY26 (YoY). On a sequential basis, it declined by 27.16% from Rs 5,606.22 million in Q4FY26 (QoQ). Total Income: Total income for Q1FY27 was Rs 4,114.76 million, marking an increase of 309.56% compared to Rs 1,004.68 million in Q1FY26 (YoY) and a decrease of 27.23% from Rs 5,654.09 million in Q4FY26 (QoQ). Profit Before Tax (PBT): The company reported a PBT of Rs 759.09 million in Q1FY27, reflecting a significant turnaround from a loss of Rs 312.78 million in Q1FY26 (YoY). Sequentially, PBT dropped by 42.42% compared to Rs 1,318.32 million in Q4FY26 (QoQ). Net Profit for the Period (PAT): The consolidated net profit for Q1FY27 reached Rs 527.44 million, recovering from a net loss of Rs 239.44 million in Q1FY26 (YoY). On a sequential basis, net profit decreased by 44.96% from Rs 958.29 million in Q4FY26 (QoQ). Total Comprehensive Income: The company posted a total comprehensive income of Rs 523.81 million in Q1FY27, compared to a loss of Rs 242.08 million in Q1FY26 (YoY) and an income of Rs 1,081.82 million in Q4FY26 (QoQ). Earnings Per Share (EPS): Basic and Diluted EPS for Q1FY27 stood at Rs 5.21, reflecting a recovery from Rs (2.10) in Q1FY26 (YoY), but a decrease from Rs 8.05 in Q4FY26 (QoQ). Standalone Financial Highlights: Revenue from Operations: Standalone revenue for Q1FY27 was Rs 3,993.78 million, demonstrating a massive growth of 318.99% from Rs 953.20 million in Q1FY26 (YoY), while experiencing an 8.97% decline from Rs 4,387.10 million in Q4FY26 (QoQ). Total Income: Standalone total income stood at Rs 4,007.46 million in Q1FY27, up by 314.00% compared to Rs 968.02 million in Q1FY26 (YoY) and down by 9.22% from Rs 4,414.53 million in Q4FY26 (QoQ). Net Profit for the Period (PAT): Standalone net profit for Q1FY27 was Rs 566.27 million, turning profitable compared to a net loss of Rs 134.05 million in Q1FY26 (YoY). Sequentially, PAT contracted by 13.80% from Rs 656.94 million in Q4FY26 (QoQ). Earnings Per Share (EPS): Basic and Diluted EPS for the standalone entity for Q1FY27 was Rs 5.02, turning positive from Rs (1.19) in Q1FY26 (YoY) but lower than the Rs 5.83 reported in Q4FY26 (QoQ). Business Highlights: Initial Public Offering (IPO): Subsequent to the quarter ended June 30, 2026, the company successfully completed its IPO of 11,646,246 equity shares (face value of Rs 1 each) at an issue price of Rs 807 per equity share for investors. The issue comprised a fresh issue of Rs 2,000.00 million and an offer for sale of Rs 7,396.96 million. The equity shares were successfully listed on the National Stock Exchange (NSE) and BSE Limited on August 17, 2026. Strategic Stake Acquisition: During Q1FY27, the Holding Company acquired an additional stake of 4.53% in Prognosys Medical Systems Private Limited (PMS) from existing shareholders. This acquisition increased the Holding Company's cumulative shareholding in PMS from 65.47% to 70.00%. Employee Stock Option Plan: Shareholders of the Holding Company approved the creation of an ESOP pool of 2,819,000 options under the "Employee Stock Option Plan 2025" (ESOP 2025). As of June 30, 2026, no stock options had been granted. Tax Updates: The Income Tax department had raised tax demands aggregating to Rs 208.71 million plus interest and penalty following a survey completed in March 2024. The Company has paid Rs 78.95 million under protest in connection with the survey and filed an appeal with the Commissioner Income Tax (Appeals). Sriram Natarajan, Executive Director & Chief Executive Officer, Molbio Diagnostics, said: "FY27 is a milestone year for Molbio, marking our transition to a listed company. I would like to thank our shareholders, employees, customers and partners for the trust they have placed in Molbio through our recent listing, and we remain committed to delivering on that trust through consistent execution. I am pleased to report that we have begun the year on a strong note, with healthy growth across both revenue and profitability in Q1. However, our business continues to have a non-linear revenue profile, with performance varying across quarters. We therefore believe it is important to assess our performance on a full-year basis. During the quarter, certain export orders pertaining to Q4FY26, amounting to approximately Rs 57 crore, were deferred due to the prevailing situation in the Gulf and were subsequently recognised in Q1FY27. Total Income for Q1FY27 stood at Rs 411.48 crore, with EBITDA at Rs 103.68 crore against a loss of Rs 14.50 crore in Q1FY26. Growth continues to be led by test-kit consumption across the 12,500+ Truenat® devices sold in 90+ countries. We entered FY27 with meaningful capacity headroom - FY26 device and test-kit utilisation at 42% and 58%, respectively, positioning us for volume-led scale-up without near-term incremental capex. Our pipeline of 34 additional assays across 22 diseases remains on track and will be a key long-term driver as we extend beyond infectious disease into oncology and other non-communicable areas. Internationally, we are deepening our presence across Africa and Southeast Asia, entering Latin America, and progressing regulatory pathways in developed markets, including CE-IVDR for our CTNG Test. Following our listing on August 17, 2026, deployment of the net issue proceeds is underway across capex for automation and building our R&D; facility in Bengaluru. We remain focused on disciplined execution, sustained R&D; intensity and improving cash flow quality as our international and acquired businesses scale." Result PDF